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Abstract
The regimen of cytarabine, aclarubicin and G-CSF (CAG) has been widely used in China and Japan for treatment of
acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). We searched literature on CAG between 1995
and 2010 and performed a meta-analysis to determine its overall efficacy using a random-effects or fixed-effects
model. Thirty five trials with a total of 1029 AML (n = 814) and MDS (n = 215) patients were included for analysis.
The CR rate of AML (57.9%) was significantly higher than that of MDS (45.7%) (p < 0.01). No difference in CR was
noted between the new (56.7%) and relapsed/refractory AML (60.1%) (p > 0.05). The CR rate was also significantly
higher in patients with favorable (64.5%) and intermediate (69.6%) karyotypes than those with unfavorable one
(29.5%) (p < 0.05). Remarkably, the CR rate of CAG was significantly higher than those of non-CAG regimens (odds
ratio 2.43). CAG regimen was well tolerated, with cardiotoxicity in 2.3% and early death in 5.2% of the cases. In
conclusion, CAG regimen was an effective and safe regimen for the treatment of AML, and may be more effective
than non-CAG regimens. Randomized controlled trials are strongly recommended to evaluate its efficacy and safety
in comparison with the current standard treatment.
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Introduction
Intensive chemotherapy can achieve complete remission
(CR) in 60% - 80% of patients with newly diagnosed de
novo acute myeloid leukemia (AML) [1,2]. However,
current therapy is still unsatisfactory in patients with
high-risk AML including elderly, relapsed, refractory,
and secondary AML. Intensive chemotherapy is gener-
ally unsatisfactory in these patients because of drug
resistance, poor performance status (PS), dysfunction of
multiple organs, and high treatment-related toxicities,
leading to high early death (ED) rate [3-6]. Novel agents
and regimens are being developed for this group of
patients [2,7-10].
Aclarubicin is an oligosaccharide anthracycline, and an
antineoplastic antibiotic. It can intercalate into DNA
and interact with topoisomerase I and II, thereby inhi-
biting DNA replication and DNA repair [11]. This agent
is less cardiotoxic than doxorubicin and daunorubicin
[12,13]. In 1995, a Japanese group reported a new che-
motherapy regimen for AML treatment, which inte-
grated granulocyte colony-stimulating factor (G-CSF)
priming into the combination of low-dose cytarabine
(Ara-C) and aclarubicin (CAG regimen) [14]. The CAG
regimen consists of low-dose Ara-C 10 mg/m
2,S QQ 1 2
hr on days 1-14, aclarubicin 7 mg/m
2, QD on days 1-8,
or 14 mg/m
2, IV QD on days 1-4, and G-CSF 200 μg/
m
2, SQ QD on days 1-14. The rationale for the regimen
includes: (1) G-CSF priming has been found to preferen-
tially potentiate Ara-C and anthracycline- mediated
cytotoxicity on AML cells and AML progenitor cells
(CFU-AML), presumably by enhancing G0 resting AML
cells into the cell cycle [15]; (2) prolonged exposure to
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ing of CFU-AML [16]; (3) Aclarubicin is effective
regardless of multi-drug resistance gene status [17]; (4)
CAG combination may inhibit the self-renewal capacity
of CFU-AML and leukemia stem cells [18]. Since then,
CAG regimen has been used to treat AML and myelo-
dysplastic syndrome (MDS) patients widely, particularly
for high-risk and elderly patients, in China and Japan.
However, the overall efficacy and safety of CAG regimen
have not been adequately evaluated. All published stu-
dies on CAG were small phase II studies with significant
variation in clinical outcomes. In this study, we per-
formed a systematic review and meta-analysis to assess
the overall treatment efficacy and the adverse events of
the CAG regimen.
Materials and methods
Data source
The databases of PubMed, Wanfang Data, as well as
American Society of Hematology (ASH) and American
Society of Clinical Oncology (ASCO) annual meeting
abstracts were searched for articles published in English,
Chinese and Japanese languages between January 1995
and December 2010. Eligible studies were relevant clini-
cal trials on AML and MDS patients treated with CAG
regimen. Key words used were CAG, chemotherapy, leu-
kemia, and MDS. An independent search using the cita-
tion database Wanfang Data (http://www.wanfangdata.
com) was also performed to identify those publications
in Chinese only.
Study selection
The publications identified were carefully screened. Pre-
clinical studies, case reports and reviews were excluded.
Several reports had duplicate or overlapping informa-
tion. Only the latest updated reports were included for
meta-analysis. For two studies by Qian’s group [19,20],
it was impossible to decipher whether duplicate or over-
lapping information was used. These were treated as
individual studies. Efforts also were made to contact the
Chinese investigators to clarify study issues. We also
contacted Japanese investigators to obtain original publi-
cations in Japanese with English abstracts.
Clinical endpoints
We extracted details on study characteristics, patient
characteristics, treatment information, results and fol-
low-up from the selected trials. Two investigators
reviewed the data independently (GW and DL). The pri-
mary end point of the meta-analysis was CR rate. AML
CR was defined using the criteria developed by an Inter-
national Working Group [21]. The criteria for refractory
a n dr e l a p s e dA M Lw e r ed e s c r i b e dp r e v i o u s l y[ 2 2 ] .T h e
criteria for karyotype classification have evolved over the
past decades [4,23,24]. In general, the 35 studies chosen
for final analysis followed the standard definitions
described above. CR rates and side effects were carefully
reviewed and compiled. Two major side effects, cardio-
toxicity and early death (ED), were chosen for further
analysis since these two toxicities are generally more
objective. In studies which did not clearly define the cri-
teria of cardiotoxicity, the toxicity was counted as being
present when a study reported mortality cases due to
cardiac causes. There were different criteria for ED defi-
nition among the studies. All deaths of any cause within
8 weeks of induction therapy were counted as ED in
this meta-analysis since most of the early death reports
in this series were within 8 weeks of induction therapy.
This would also reduce the chance of under-reporting
the toxicity. Standard age definitions were used, i.e.
young AML: age < = 60; Elderly AML: age >60.
Statistical analysis
All statistical analyses were performed using version 2 of
the Comprehensive MetaAnalysis program (Biostat, Eng-
l e w o o d ,N J ,U S A ) .T h eC Rr a t e s of patients treated with
CAG regimen were directly extracted from individual
studies. For subgroup analysis of patients with newly
diagnosed, refractory/relapsed AML, and MDS or AML
transformed from MDS (MDS/t-AML) patients, numbers
of patients in CR were extracted from individual studies
and CR rates were recalculated from the derived data.
For studies with a control group, the odds ratio (OR) of
CR rates was also calculated. For the meta-analysis, both
fixed-effects and random-effects models were considered.
For each meta-analysis, the Cochrane’sQs t a t i s t i cw a s
first calculated to assess the heterogeneity of the included
studies. For p values less than 0.1, the assumption of
homogeneity was deemed invalid, and the random-effects
model was used only after substantial efforts were made
to explore the possible reasons for the heterogeneity.
Otherwise, data were assessed using both fixed-effects
and random-effects models. We used the Begg and Egger
tests to evaluate the presence of publication bias regard-
ing the primary end point CR rates. A two-tailed p value
of less than 0.05 was deemed statistically significant. All
the statistical analyses were done by GW and DL.
Results
Selection of studies
Using the key words, our search yielded a total of 135
studies on CAG. Fifty seven studies were irrelevant to
CAG regimen trials, and were excluded. Another 32 stu-
dies were eliminated due to inadequate information,
duplicate and/or overlap reporting. Nine case reports and
2 studies focus on other kinds of leukemia were also
excluded. A total of 35 clinical studies were eligible for
inclusion and were used for final meta-analysis (Figure 1).
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Page 2 of 13Characteristics of studies included in the meta-analysis
Thirty five trials were included in the present analysis,
with a total of 1029 patients accrued. Characteristics of
the 35 trials are listed in Tables 1 and 2. Twenty three
of the studies were on AML. Six of the studies focused
on MDS. The rest 6 studies enrolled both AML and
MDS patients. A total of 814 AML patients were
accrued in 29 studies. Among the 814 AML patients,
327 patients had newly diagnosed AML, 370 patients
were relapsed/refractory (R/R) AML. AML status of 117
patients was not specified in 7 studies [19,20,25-29].
The age varied widely, ranging from 15 to 88 years old.
Two studies did not indicate the age range (Table 1).
Unfortunately, median age was not specified in most
studies. Among the 814 patients, 367 were elderly AML
patients (45.1%). Cytogenetic characteristics from 203
AML patients were reported in 6 studies. These patients
were grouped into 3 categories according to the karyo-
types: favorable, intermediate and unfavorable. CAG
regimen was compared to historical controls using non-
CAG induction regimens in 7 studies with 327 patients.
The number of CAG cycles was clearly reported in 17
studies involving 397 patients, of whom 144 (36.2%)
were induced twice with CAG.
Publication bias
No evidence of publication bias was detected for the pri-
mary end point, CR, of this study by either the Begg or
Egger test (Begg test, p = 0.35; Egger test, p = 0.15).
Efficacy of CAG regimen for all AML and high-risk MDS/
transformed AML
The heterogeneity test of CR event rates from the 35 stu-
dies revealed Q 59.431, p 0.025, I
2 32.695, indicating the
CR event rates were highly variable. Therefore, the CR
event rates were calculated using the random-effects
model (Figure 2). The overall CR rate for the 1029 patients
was 53.7% (95% CI, 49.7%-57.6%). Data available from 29
trials with 814 AML patients showed that the CR rate was
57.9% (95% CI, 53.0%-62.7%). As for the 215 patients with
MDS and transformed AML (MDS/t-AML) from 12 trials,
the CR rate was 45.7% (95% CI, 39.0%-52.4%) (Figure 2).
We also compared CAG in AML versus MDS. The
higher CR rate in AML (57.9%) than in MDS (45.7%)
was statistically significant (p = 0.004) (Figure 2). This is
in agreement with the past observations that AML
responds better to chemotherapy in general than MDS.
Among AML patients, the median OS was 15 months
(range 9-28 months). The number of CAG cycles was
specified in 17 studies involving 397 patients, of whom
144 (36.2%) were induced twice with CAG. Of the
patients who received one cycle, 46.60% (185/397) went
into CR, another 8.31% (33/397) of the patients achieved
CR after re-induction with CAG.
Efficacy of CAG regimen for newly diagnosed vs relapsed/
refractory AML
There were a total of 327 new AML patients from 14
studies, and 370 patients with relapsed/refractory (R/R)
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Figure 1 Flow chart for study selection in the meta-analysis.
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Page 3 of 13AML from 15 studies. Four of these studies enrolled
both new and R/R AML (Table 3 and Figure 3). These
four studies were separated into new and R/R AML
groups for meta-analysis. Another seven studies did not
specify AML status of the rest 117 patients. These 117
patients were therefore excluded for this comparison
(Table 3). The heterogeneity test of CR event rates of
these studies revealed Q 48.608, p 0.009, I
2 42.396, indi-
cating the CR event rates were highly variable. There-
fore, the CR event rates were calculated using the
random-effects model (Figure 3). The CR rate for the
newly diagnosed AML patients was 56.7% (95% CI,
51.1%-62.0%). The CR rate of the 370 R/R AML patients
was 60.1% (95% CI, 50.5%-68.9%) (Figure 3). Interest-
ingly, no significant difference in CR rate was noted
between the newly diagnosed and R/R AML patients (p
= 0.539) (Table 3 and Figure 3), suggesting that this
novel regimen may overcome AML resistance.
CR rates in AML patients according to karyotypes
Cytogenetic characteristics from 203 AML patients were
reported in 6 studies (Table 4). The heterogeneity test
of CR event rates revealed Q 35.323, p 0.004, I
2 54.707,
indicating the CR event rat e sw e r eh i g h l yv a r i a b l e .
Therefore, the CR event rates were calculated using the
random-effects model (Figure 4). The CR rates were
Table 1 Efficacy, cardiotoxicity and early death rate of CAG in AML
Study (ref) Year No.
Patients
*
Median age
(range)
Aclarubicin dosage AML
No.
AML CR
No.
AML CR
%
OS (m)
(range)
CT
No.
ED
No.
Yamada [14] 1995 18 44 (18-74) 10-14 mg/m
2 × 4d 18 15 83 17 (2-28) 0 0
Saito [35] 1995 18 NR(18-74) 10 or 14 mg/m
2 × 4d 18 15 83 15 (1-35) 1 0
Saito [36] 1996 28 NR(18-74) 10 or 14 mg/m
2 × 4d 28 24 86 17 (1-47) 0 0
Tabata [37] 1998 76 NR(60-83) 14 mg/m
2 ×4 d 8 5 6 3 N A N A N A
Saito [38] 2000 69 51 (15-82) 10 or 14 mg/m
2 ×4 d 5 1 3 1 6 2 N A 0 0
Hirayama
[39]
2003 18 NR(65-80) 14 mg/m
2 × 4d 9 6 67 9 (1-43) 0 1
Li [26] 2005 112 47 (15-81) 14 mg/m
2 ×4 dor 8 mg/m
2
×8 d
99 44 44 NA 0 1
Kong [40] 2005 20 NR(18-80) 10-14 mg/m
2 ×4 d 2 0 1 1 5 5 N A 0 0
Yang [41] 2005 16 NR(60-82) 6 mg/m
2 × 8d 16 9 56 NA 0 1
Huang [25] 2005 30 NR(15-67) 5-7 mg/m
2 ×8 d 3 0 2 2 7 3 N A 0 1
Qian [19] 2005 21 NR(15-81) 10 mg/d × 8d 21 14 67 NA 0 2
Xie [42] 2006 25 NR(55-78) 10 mg/m
2 ×4 d 2 5 1 2 4 8 N A 0 3
Liu [27] 2006 13 NR(18-77) 10-14 mg/m
2 × 4d 13 5 39 NA 0 0
Wang [43] 2006 11 NR(25-72) 10 mg/m
2 × 8d 11 4 36 NA 0 0
Wu [44] 2007 15 NR(60-84) 7 mg/m
2 × 8d 15 8 53 NA 1 1
Qian [20] 2007 50 65 (60-81) 10 mg/d × 8d 50 29 58 14 (1-60) 0 4
Su [29] 2007 16 NR 20 mg/d × 4d 16 9 56 NA 0 0
Guo [45] 2007 8 NR(18-56) 5-7 mg/m
2×5d 8 4 50 NA 0 0
Chen [46] 2008 75 NR(60-85) 10 mg/d × 8d 34 23 68 NA 0 0
Sang [47] 2008 45 NR(60-73) 7 mg/m
2 × 8d 23 9 39 NA 0 1
Bian [48] 2008 46 NR(18-72) 10-14 mg/m
2 ×4 d 2 6 2 0 7 7 N A 0 0
Chai [49] 2009 17 NR 15 mg/m
2×7d 17 8 47 NA 0 0
Zhu [50] 2009 50 NR(15-69) 10 mg/d × 8d 30 14 47 NA 0 1
Ni [51] 2009 70 NR(22-85) 14 mg/m
2 × 4d 61 34 56 28 (1-89) 0 3
Feng [52] 2010 32 NR(60-74) 5-7 mg/m
2 × 8d 16 9 56 NA 0 0
Ma [28] 2010 31 NR(19-71) 14 mg/m
2 ×4 d 2 6 1 4 5 4 N A 0 0
Li [53] 2010 38 NR(19-61) 5-7 mg/m
2 ×8 d 1 8 1 4 7 8 N A 0 0
Liang [54] 2010 54 NR(17-82) 5-7 mg/m
2 ×8 d 3 9 2 1 5 4 N A 1 7
Suzushima
[55]
2010 68 76 (60-88) 14 mg/m
2 × 4d 68 33 49 9 (0-56) NA 15
Abbreviations: AML: acute myeloid leukemia; Ref: references; NA: not available; NR: not reported; *: total number of AML and MDS patients; m: month; CR:
complete remission; OS: overall survival; CT: cardiotoxicity; ED: early death; CAG: cytarabine, aclarubicin and G-CSF.
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77.5%) and 29.5% (95% CI, 19.7%-41.8%) in favorable,
intermediate and unfavorable groups, respectively. Sta-
tistical difference of the CR rates was noted between the
favorable and unfavorable groups (p = 0.018) as well as
between the intermediate and unfavorable groups (p <
0.001). No significant difference was present between
the favorable and intermediate groups (p = 0.705) (Fig-
ure 4).
CAG vs non-CAG regimens for AML induction
Using historical controls, CAG regimen was compared
with non-CAG regimens for AML induction in 7 trials.
165 patients were treated with CAG, 162 were induced
with non-CAG regimens (the regimen details are pro-
vided in the Table 5). The heterogeneity test of CR
event rates from the 7 studies revealed Q 3.631, p 0.726,
I
2 <0.001, indicating that there was no significant varia-
tion among the 7 studies. Therefore, the CR event rates
were calculated using the fixed-effects model (Figure 5).
Surprisingly, the CR rate of CAG was significantly
higher than those of other regimens, with an odds ratio
of 2.43 (95% CI, 1.52-3.88) (Figure 5).
Cardiotoxicity and early death rate of CAG
The toxicity of CAG in all reports was generally mild.
Cardiotoxicity data were reported in 33 studies with 953
patients, and ED was reported in 34 studies with 1021
patients. Cardiotoxicity rate was 2.3% (95% CI, 1.5%-
3.6%) (actuarial rate 0.42%, 4/953) (Tables 1 and 2, Fig-
ure 6). ED rate was 5.2% (95% CI, 3.5%-7.6%) (actuarial
rate 4.31%, 44/1021) (Tables 1 and 2, Figure 7). Among
AML patients, the cardiotoxicity rate was 2.4% (95% CI,
1.5%-4.0%) (actuarial rate 0.41%, 3/738), and ED rate
was 5.9% (95% CI, 3.9%-8.8%) (actuarial rate 5.09%, 41/
806). Most of the death was caused by severe infection,
cardiopulmonary dysfunction or cerebral hemorrhage.
Discussion
CAG regimen was originally designed in Japan for the
treatment of relapsed AML patients in 1995. It quickly
became popularized in China for the treatment of high-
risk AML and MDS patients due to relatively mild toxi-
city. Most of the studies were single-center non-rando-
mized trials with small sample size. CAG has not been
systematically compared with other induction regimens.
In this meta-analysis, 1029 patients with AML and MDS
were treated with CAG regimen. Two findings on CR
rate for AML are quite intriguing. Number one, there
was no significant differences in CR rates between new
(56.7%) and relapsed/refractory (60.1%) AML. This is
surprising since the CR rate is generally lower for R/R
than new AML. One possibility is that this novel CAG
regimen can overcome the drug resistance of the R/R
AML clone and lead to high CR rate. Alternatively, it
may be that the first-line induction therapy was substan-
dard in these patients from diverse institutions with dif-
ferent supportive care standards. Therefore, the relapsed
and refractory AML was still sensitive to alternative che-
motherapy. The CR rate of CAG (56.7%) for new AML
appears to be slightly lower than the CR rate of standard
“3+7” regimen (daunorubicin 45 mg/m
2 +A r a - C1 0 0
mg-200 mg/m
2) (57%-65%) [5,7,30,31] (Table 6). How-
ever, there have been no randomized studies, it is there-
fore not clear whether CAG is as effective as “3+7”.
The second finding is that, as frontline AML regimen,
CAG induced higher CR rate in AML than non-CAG
regimens (p < 0.001, odds ratio 2.43 favoring CAG). The
Table 2 Efficacy, cardiotoxicity and early death rate of CAG in MDS/t-AML
Study (ref) Year No.
Patients *
Median age (range) Aclarubicin dosage MDS/t-AML No. CR No. CR % CT No. ED No.
Saito [38] 2000 69 51 (15-82) 10 or 14 mg/m
2 ×4 d 1 8 8 4 4 0 0
Li [26] 2005 112 47 (15-81) 14 mg/m
2 × 4d or 8 mg/m
2 ×8 d 1 3 5 3 9 0 0
Sui [56] 2008 17 NR(26-73) 10-14 mg/m
2 ×4 d 1 7 6 3 5 0 0
Jin [57] 2008 14 NR(38-78) 10-14 mg/m
2 ×4 d 1 4 6 4 3 0 0
Deng [58] 2008 39 NR(52-78) 5-6 mg/m
2×7d 16 9 55 0 0
Su [59] 2009 33 60 (28-77) 10 mg/d × 8d 33 14 42 1 0
Ni [51] 2009 70 NR(22-85) 14 mg/m
2 ×4 d 9 5 5 6 0 1
Ma [28] 2010 31 NR(19-71) 14 mg/m
2 ×4 d 5 3 6 0 0 0
Li [60] 2010 20 NR(36-74) 5-7 mg/m
2 ×8 d 2 0 9 4 5 0 0
Zhu [61] 2010 46 54 (31-72) 10 mg/m
2 ×8 d 2 8 1 3 4 6 0 0
Chen [62] 2010 27 NR(21-72) 10 mg/d × 8d 27 15 56 0 0
Liang [54] 2010 54 NR(17-82) 5-7 mg/m
2 ×8 d 1 5 5 3 3 0 2
Abbreviations: AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; MDS/tAML: MDS or MDS transformed AML; Ref: references; NR: not reported; *:
total number of AML and MDS patients; CR: complete remission; OS: overall survival; CT: cardiotoxicity; ED: early death; CAG: cytarabine, aclarubicin and G-CSF.
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in 5 studies (AA regimens), and homoharringtonine plus
Ara-C (HA regimen) in two other studies. HA is only
used in China [32]. When CAG was compared with the
5 AA regimens, CAG remains superior to the AA regi-
mens in CR rate (p < 0.001, odds ratio 2.73, 95% CI
1.61-4.64). However, the studies were not randomized,
and the comparisons in those studies were made with
historical controls. It is therefore worthwhile to compare
CAG regimen with standard anthracycline plus Ara-C in
a prospective randomized study.
In this meta-analysis, the CR rate of CAG regimen for
high-risk MDS/t-AML patients was 45.7% (95% CI,
39.0%-52.4%). Aza-001 trial, a prospective randomized
study, compared azacitidine with conventional care regi-
men (best supportive care, low dose Ara-C, or intensive
chemotherapy “3+7”)i nh i g h e r - r i s kM D Sp a t i e n t s[ 3 3 ] .
The CR rate was 17% and 36% in the azacitidine group
Figure 2 Comparison of CR rates of CAG regimen in AML and MDS patients–Forest plot of CR event rates. Summary CR rates of CAG
regimen were calculated using the random-effects model. Horizontal lines through the squares represent 95% CIs. The diamonds represent the
overall CR event rate from the meta-analyses and the corresponding 95% CIs. The studies that enrolled both AML and MDS were separated into
two groups for this analysis, indicated by “-A”. Abbreviations: AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; CI: confidence
interval; CR: complete remission; CAG: cytarabine, aclarubicin and G-CSF.
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longed overall survival in the high-risk MDS patients.
CAG gained popularity in China and Japan in the past
decade because, based solely on small phase II studies, it
is widely believed to be a milder regimen than “3+7” for
high-risk and elderly AML and MDS patients. It is
therefore valuable to perform a prospective randomized
trial in high-risk elderly MDS patients to compare CAG
with “3+7” for their effects on overall survival.
There have not been many reports focusing on toxici-
ties of AML inductions. In the report of “3+7” regimen
on 326 new AML patients from the Cancer and Leuke-
mia Group B 8321 study, the overall induction mortality
was 15% [30]. Data from the Swedish Acute Leukemia
Registry from all unselected 2767 AML patients found
an overall ED (30 days from diagnosis) rate of 19%
(range 4-40% according to age) [5]. The ED rate was
10% for intensive chemotherapy group, and 34% for pal-
liative group. The data clearly supported chemotherapy
for all age groups. In a phase III randomized study com-
paring high with standard dose daunorubicin in 657
young (age ≤ 60) AML patients [7], induction mortality
was 4.5% in the standard group, 5.5% in the high dose
group (p = 0.60). This study reported cardiac toxicity of
7.2% in the standard dose group with no reduction in
ejection fraction. In a separate phase III randomized
study comparing high with standard dose daunorubicin
in 813 elderly (age ≥ 60) AML patients [31], 30-day
mortality was found to be 12% in the standard group,
11% in the high dose group (p = 0.59). Cardiac toxicity
was not specified in this study. Kantarjian’sg r o u p
reported their 15 years’ experience of induction che-
motherapy on 510 high-risk MDS patients (median age
63) [34]. The overall ED (death within 7 weeks of induc-
tion) rate was 17% (topotecan-Ara-C 6%, anthracycline-
Ara-C 17%, fludarabine-Ara-C 23%). In our analysis, it
was difficult to quantify toxicities from so many small
phase II studies, which were from diverse institutions in
China and Japan with different supportive care stan-
dards. We therefore chose two relatively objective para-
meters, cardiotoxicity and ED rate. In this analysis,
cardiotoxicity was 2.3% and ED was 5.2% among all
AML and MDS patients. For new AML patients, the ED
rate was 9.0%, whereas the ED for MDS was only 4.8%
(Table 6). Taken together all these experiences of induc-
tion efficacy and toxicities (Table 6), it appears that
CAG regimen was effective and well tolerated.
This study has severe limitations. First of all, this
study is based on 35 trials which were conducted in
China and Japan, where significant variations in suppor-
tive care may have existed. In addition, the studies were
between 1995 and 2010. Newer molecular prognostic
markers, such as FLT3 and NPM1, were not routinely
tested in most of the studies. The standard of supportive
care for AML has changed dramatically over the decade.
The toxicity data from this analysis may therefore over-
estimate the adverse events of the regimens under cur-
rent health care system. Majority of the studies were
small (only 9 of the 35 studies had 50 or more subjects).
Although all the studies used similar CAG regimens, the
dosage of aclarubicin was variable. Due to the small
sample sizes and ambiguity in reporting the AML status
in the 7 studies, it was difficult to ascertain whether the
variation of the aclarubicin dosage could have played
any role in the outcomes among the different groups of
AML (new vs R/R) and MDS/t-AML. There was no ran-
domized study among the 35 reports. CAG was com-
pared with non-CAG regimens from historical controls
in the 7 reports. The non-CAG regimens also varied.
Two of the seven reports did not include anthracyclines.
Table 3 Efficacy of CAG in newly diagnosed, relapsed and
refractory AML
Study (ref) Year Newly diagnosed
AML
R/R AML
No.
Patients
CR
No.
CR
%
No.
Patients
CR
No.
CR
%
Yamada [14] 1995 NA NA NA 18 15 83
Saito [35] 1995 NA NA NA 18 15 83
Saito [36] 1996 NA NA NA 28 24 86
Tabata [37] 1998 8 5 63 NA NA NA
Saito [38] 2000 8 5 63 43 30 70
Hirayama [39] 2003 9 6 67 NA NA NA
Li [26] 2005 NA NA NA 80 38 47
Kong [40] 2005 20 11 55 NA NA NA
Yang [41] 2005 16 9 56 NA NA NA
Xie [42] 2006 25 12 48 NA NA NA
Wang [43] 2006 NA NA NA 11 4 36
Wu [44] 2007 15 8 53 NA NA NA
Qian [20] 2007 35 23 66 12 5 40
Guo [45] 2007 NA NA NA 8 4 50
Chen [46] 2008 34 23 68 NA NA NA
Sang [47] 2008 23 9 39 NA NA NA
Bian [48] 2008 NA NA NA 26 20 77
Chai [49] 2009 NA NA NA 17 8 47
Zhu [50] 2009 NA NA NA 30 14 46
Ni [51] 2009 27 19 70 34 15 44
Feng [52] 2010 16 9 56 NA NA NA
Ma [28] 2010 NA NA NA 11 6 55
Li [53] 2010 NA NA NA 18 14 78
Liang [54] 2010 23 14 61 16 7 44
Suzushima
[55]
2010 68 33 49 NA NA NA
Abbreviations: AML: acute myeloid leukemia; MDS: myelodysplastic syndrome;
Ref: references; NA: not available; m: month; CR: complete remission; OS:
overall survival; CAG: cytarabine, aclarubicin and G-CSF.
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Page 7 of 13Figure 3 Comparison of complete remission (CR) rates of CAG regimen in new, refractory and relapsed AML patients–Forest plot of
CR event rates. Summary CR rates of CAG regimen were calculated using the random-effects model. Horizontal lines through the squares
represent 95% confidence interval (CI). The diamonds represent the overall CR event rate from the meta-analyses and the corresponding 95%
CIs. The studies that enrolled both new and relapsed/refractory AML were separated into two groups for this analysis, indicated by “-A”. CAG:
cytarabine, aclarubicin and G-CSF.
Table 4 Efficacy of CAG regimen in AML patients according to karyotypes
Study Year Total
No.
patients
No. Patients No. CR CR %
Favorable Intermediate Unfavorable Favorable Intermediate Unfavorable Favorable Intermediate Unfavorable
Saito [38] 2000 63 6 27 30 5 19 9 83 70 29
Hirayama
[39]
2003 9 1 4 4 1 3 2 100 75 50
Qian [20] 2007 40 2 28 10 1 19 4 50 68 40
Chen [46] 2008 34* 6 16 9 6 13 2 100 81 22
Zhu [50] 2009 30 4 21 5 2 12 0 50 57 0
Ma [28] 2010 31 3 18 10 1 14 2 33 78 20
Abbreviation: AML: acute myeloid leukemia; CR: complete remission; CAG: cytarabine, aclarubicin and G-CSF; *: karyotyping from 3 patients was indeterminate.
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Page 8 of 13Figure 4 Comparison of the CR rates of CAG regimen in AML patients according to karyotypes. Summary CR rates of CAG regimen were
calculated using the random-effects model. Horizontal lines through the squares represent 95% CIs. The diamonds represent the overall CR
event rate from the meta-analyses and the corresponding 95% CIs.
Table 5 CR rates of CAG and non-CAG regimens in AML patients
Study Year Total No.
patients
No. Patients No. CR CR %
CAG Non-CAG CAG Non-CAG CAG Non-CAG
Saito [35] 1995 35 18 17
1 15 11 83 65
Chen [46] 2008 75 34 41
2 23 16 68 39
Sang [47] 2008 45 23 22
3 9 7 39 32
Bian [48] 2008 46 26 26
4 20 10 77 38
Zhu [50] 2009 50 30 20
5 14 6 47 30
Li [53] 2010 38 18 20
6 14 14 78 70
Feng [52] 2010 32 16 16
7 9 7 56 44
Abbreviation: AML: acute myeloid leukemia; CR: complete remission; CAG: cytarabine, aclarubicin and G-CSF;
1: HD-Ara-C+M/ME (high-dose cytarabine plus mitoxantrone with or without etoposide);
2: TA/HA (pirarubicin plus cytarabine/homoharringtonine plus cytarabine);
3: DA/HA/IA (daunorubicin plus cytarabine/homoharringtonine plus cytarabine/idarubicin plus cytarabine);
4: DAH/MAE (daunorubicin plus cytarabine plus homoharringtonine/mitoxantrone plus cytarabine plus etoposide);
5: DA/IA/MA (daunorubicin plus cytarabine/idarubicin plus cytarabine/mitoxantrone plus cytarabine);
6: HAG (homoharringtonine plus cytarabine plus GCSF);
7: HA (homoharringtonine plus cytarabine).
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Page 9 of 13Figure 5 Comparison of the CR rates of CAG regimen and non-CAG regimens in AML patients. Summary Odds ratio (OR) of CR rates of
CAG regimen versus non-CAG regimen was calculated using the fixed-effects model. Horizontal lines through the squares represent 95% CIs.
The diamonds represent the overall OR from the meta-analyses and the corresponding 95% CIs. An OR greater than 1 implies that the CR event
is more likely in the CAG group.
Figure 6 Cardiotoxicity (CT) rate of CAG regimen in AML and MDS patients–Forest plot of CT event rates. Summary CT rates of CAG
regimen were calculated using the random-effects model. Horizontal lines through the squares represent 95% CIs. The diamonds represent the
overall CT event rate from the meta-analyses and the corresponding 95% CIs.
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Page 10 of 13Figure 7 Early death (ED) rate of CAG regimen in AML and MDS patients. Summary ED rates of CAG regimen were calculated using the
random-effects model. Horizontal lines through the squares represent 95% CIs. The diamonds represent the overall ED event rate from the
meta-analyses and the corresponding 95% CIs.
Table 6 CR rates, ED and Cardiotoxicity rates of CAG and non-CAG induction regimens in new AML and MDS
Study (ref) Disease No. Patients Age Median age Regimen CR % ED % CT %
CALGB 8321 [30] AML 326 15-83 NA DNR (45 mg/m
2) +Ara-C 61 15
1 NR
ECOG [7] AML 582 17-60 48 DNR (45 mg/m
2) +Ara-C
DNR (90 mg/m
2) +Ara-C
57
71
4.5
1
5.5
1
7.2
7.9
SALR [5] AML 2767 16-97 72 anthracycline + Ara-C 65 10
2 NR
HOVON and SAKK [31] AML 813 60-83 67 DNR (45 mg/m
2) +Ara-C
DNR (90 mg/m
2) +Ara-C
54
64
11
2
12
2
NR
CAG AML 327 18-88 NA CAG 57 9.0
3 2.8
Fenaux [33] MDS 358 38-88 69 Azacitidine
CCR
17
8
11
4
9
4
NR
Kantarjian [34] MDS 510 17-88 63 TA/FA/CAT/IA/DA 55 17
5 NR
CAG MDS 215 26-78 NA CAG 45.7 4.8
3 3.1
Abbreviations: AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; Ref: references; NR: not reported; CR: complete remission; NA: not available; ED:
early death; CT: cardiotoxicity; DNR: daunorubicin; Ara-C: cytarabine; 3+7: anthracycline plus cytarabine; CAG: cytarabine, aclarubicin and G-CSF; CCR: conventional
care regimen; TA: Topotecan plus Ara-C; FA: Fludarabine plus Ara-C; CAT: Topotecan plus Ara-C plus cyclophosphamide; DA/IA: daunorubicin or idarubicin plus
Ara-C; CALGB: Cancer and Leukemia Group B; ECOG: Eastern Cooperative Oncology Group; SALR: Swedish Acute Leukemia Registry; HOVON: Leukemia Working
Group of the Dutch-Belgian Cooperative Trial Group for Hematology-Oncology; SAKK: Swiss Group for Clinical Cancer Research;
Superscript numerical indicates the definitions of early death from different studies. 1: induction mortality (time frame not specified); 2: mortality within 30 days
from diagnosis; 3: mortality within the first 8 weeks of induction treatment; 4: mortality during first 3 months; 5: mortality within 7 weeks of induction therapy.
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Page 11 of 13It is therefore possible that the superiority of CAG over
non-CAG regimen may have been overestimated, even
when the more stringent fixed-effects model was used.
Estimation of CR event rates using random-effects
model may minimize the inherent variances. Finally,
CAG regimen is used exclusively in China and Japan. It
is not clear whether similar outcome is reproducible in
the Western countries.
In conclusion, CAG regimen was effective and safe for
the treatment of AML and MDS patients. Its activity
may vary among these patients with significantly higher
CR rates observed in AML than MDS. It was as active
in new AML as in relapsed and refractory AML. CAG
regimen may be more effective than non-CAG regimen
with the CR rate of CAG regimen significantly higher
than those of non-CAG induction regimens in AML
patients. This regimen was well tolerated with low cardi-
otoxicity and ED rate. We strongly recommend that
CAG regimen be compared with standard anthracycline
plus Ara-C in a prospective randomized study, particu-
larly in high-risk and elderly AML and MDS patients.
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